Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
American Federation of State, County and Municipal Employees District Council 37 Health & Security Plan v. Allergan, Inc.
Case Number:
1:17-cv-06684
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
November 15, 2018
Pharma Cos. Must Hand Over Generic Restasis Plans In MDL
A federal judge has denied three pharmaceutical companies' move to quash subpoenas for information on their plans to make generic substitutes of Allergan’s drug Restasis in multidistrict litigation over its alleged efforts to delay the generic versions’ launch, saying in-house counsel can view the data without compromising confidentiality.
-
November 14, 2018
Allergan Cuts A Few State Claims In Restasis MDL
Health benefits providers that refunded members for the cost of Allergan's dry-eye medication Restasis will be able to move forward on the majority of the state law claims the drugmaker wanted thrown out, a New York federal judge overseeing multidistrict antitrust litigation has ruled.
-
October 18, 2018
Allergan Must Produce CEO's Tribal Patent Docs In MDL
A New York federal judge has ordered Allergan to produce documents from the files its CEO and other senior executives on a deal that transferred patents to a Native American tribe for plaintiffs in multidistrict litigation accusing the drugmaker of illegally delaying a generic version of its dry-eye medication Restasis.